MARKER THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
MARKER THERAPEUTICS, INC. (MRKR) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $153.52 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-05-15
- MARKER THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $153.52K, a 40.47% decline year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $151.90K, a 40.59% decline year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $222.39K, a 12.35% decline year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $259.17K, a 2.60% increase year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $891.34K, a 12.07% decline from fiscal 2021.
- MARKER THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $1.01M, a 71.79% increase from fiscal 2020.
- MARKER THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $590.04K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $153.52K 10-Q · filed 2023-05-15 | $305.42K derived: sum of 2 quarters · filed 2023-05-15 | $527.80K derived: sum of 3 quarters · filed 2023-05-15 | $786.97K derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | $151.90K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $374.28K derived: sum of 2 quarters · filed 2023-03-22 | $633.45K derived: sum of 3 quarters · filed 2023-03-22 | $891.34K 10-K · filed 2023-03-22 |
| 2022-09-30 | $222.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $481.56K derived: sum of 2 quarters · filed 2022-11-10 | $739.45K 10-Q · filed 2022-11-10 | $995.14K derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-06-30 | $259.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $517.06K 10-Q · filed 2022-08-11 | $772.76K derived: sum of 3 quarters · filed 2023-05-15 | $1.03M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-03-31 | $257.89K 10-Q · filed 2023-05-15 | $513.59K derived: sum of 2 quarters · filed 2023-05-15 | $767.31K derived: sum of 3 quarters · filed 2023-05-15 | $1.02M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $255.70K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $509.42K derived: sum of 2 quarters · filed 2023-03-22 | $762.03K derived: sum of 3 quarters · filed 2023-03-22 | $1.01M 10-K · filed 2023-03-22 |
| 2021-09-30 | $253.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $506.33K derived: sum of 2 quarters · filed 2022-11-10 | $757.96K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $252.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $504.23K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $251.63K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $590.04K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |